This feasibility study will attempt to fill in the current gap in effective preventive interventions for pregnant mothers at risk. Recent evidence in postpartum mothers indicates that high peripartum oxytocin levels are associated with enhanced maternal behavior and low levels with depression.Therefore, the investigators will test the therapeutic effects of oxytocin (OXT). It is hypothesized that administration of intranasal oxytocin (IN-OXT) (total daily dose 48 IU) over the course of four days from as early as day one postpartum in comparison to placebo will 1) enhance mother-infant bonding, 2) reduce depressive and posttraumatic symptoms at 5 days postpartum, and 3) facilitate optimal child development.